Assorted News from the Last Week:
While new treatments for leukemia have improved outcomes for many patients, children with Down syndrome have not benefited as much. These young people are at increased risk for acute lymphoblastic leukemia (ALL) and have higher rates of relapse and treatment-related harm. Researchers at the National Cancer Institute (NCI) have developed a way to potentially increase the effectiveness of T cell–based immunotherapy treatments, such as CAR T-cell therapy, against solid tumors. Researchers have reported that soy expansion and the subsequent increase of pesticide use in Brazil’s Cerrado and Amazon biomes may correlate with an increased risk of mortality among pediatric patients with acute lymphoblastic leukemia (ALL). Forty participating laboratories, including Foundation Medicine, will participated in the National Cancer Institute’s (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with cancer.
FDA accepts NDA for Day One Biopharmaceutical’s Tovorafenib in pediatric low-grade glioma.
A collection of papers (listed below) from the St. Jude focus groups with bereaved parents. Pediatric cancer outcomes have significantly improved, and yet this success is not spread equally across cancer types or patients (a review article).Upcoming Webinars, Online Opportunities, and Meetings:
Triage Cancer will offer a webinar on Cancer Caregivers on November 15 at 11:30 ET about the rights of caregivers at work, how to replace lost wages while acting as a caregiver, and practical tips to support caregivers. Learn more and register.
